New Oncology Indications Should Continue Denosumab’s Upward Trajectory
Executive Summary
Already on an upward trajectory in oncology uses, Amgen’s denosumab, known as Prolia and Xgeva, got a bit of a boost with FDA approval of two new indications for treatment-induced bone loss in prostate and breast cancer – though neither is expected to add much to the bottom line.
You may also be interested in...
Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.
Sanofi's Deal With Medco/UBC Seeks Payer Perspective To Inform Drug R&D, Marketing
The multi-year, global data, research and consulting agreement will focus primarily on drugs in Phase II or III.
Beauty Of Amgen Bone Drug Results Is In Eye Of The Beholder
Top-line results from Phase III bone metastasis prevention trial lift stock price and inspire bullish headlines for Amgen. But vital figures and proof of clinical benefit are missing, making study tougher to interpret.